Terms: = Breast cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Treatment
45 results:
1. RAS‑stimulated release of exosomal
Kim O; Tran PT; Gal M; Lee SJ; Na SH; Hwangbo C; Lee JH
Int J Mol Med; 2023 Sep; 52(3):. PubMed ID: 37503759
[TBL] [Abstract] [Full Text] [Related]
2. Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines.
Tawfeeq N; Lazarte JMS; Jin Y; Gregory MD; Lamango NS
Oncotarget; 2023 Mar; 14():243-257. PubMed ID: 36961909
[TBL] [Abstract] [Full Text] [Related]
3. Role of a Mixture of Polyphenol Compounds Released after Blueberry Fermentation in Chemoprevention of Mammary Carcinoma: In Vivo Involvement of miR-145.
Mallet JF; Shahbazi R; Alsadi N; Saleem A; Sobiesiak A; Arnason JT; Matar C
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835085
[TBL] [Abstract] [Full Text] [Related]
4. Spontaneous rupture of a solitary oligometastatic hepatic melanoma.
Tiong J; Rajagopalan A; Jaya J; Sritharan M
BMJ Case Rep; 2023 Feb; 16(2):. PubMed ID: 36731945
[TBL] [Abstract] [Full Text] [Related]
5. Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer.
Sivakumar S; Jin DX; Tukachinsky H; Murugesan K; McGregor K; Danziger N; Pavlick D; Gjoerup O; Ross JS; Harmon R; Chung J; Decker B; Dennis L; Frampton GM; Molinero L; Oesterreich S; Venstrom JM; Oxnard GR; Hegde PS; Sokol ES
Nat Commun; 2022 Dec; 13(1):7495. PubMed ID: 36470901
[TBL] [Abstract] [Full Text] [Related]
6. Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations.
Li K; Cao L; Li C; Wu J; Chen B; Zhang G; Li X; Wen L; Jia M; Wei G; Lin J; Li Y; Zhang Y; Mok H; Ren C; Wang Y; Qi X; Guo L; Che Y; Liao N
Cancer Med; 2023 Mar; 12(5):5195-5208. PubMed ID: 36404592
[TBL] [Abstract] [Full Text] [Related]
7. Induction of apoptosis and suppression of Ras gene expression in MCF human breast cancer cells.
Saremi S; Kolahi M; Tabandeh MR; Hashemitabar M
J Cancer Res Ther; 2022; 18(4):1052-1060. PubMed ID: 36149161
[TBL] [Abstract] [Full Text] [Related]
8. KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer.
Shimozaki K; Shinozaki E; Yamamoto N; Imamura Y; Osumi H; Nakayama I; Wakatsuki T; Ooki A; Takahari D; Ogura M; Chin K; Watanabe M; Yamaguchi K
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1273-1283. PubMed ID: 35438321
[TBL] [Abstract] [Full Text] [Related]
9. Diagnosis and treatment of ERBB2-Positive Metastatic Colorectal cancer: A Review.
Strickler JH; Yoshino T; Graham RP; Siena S; Bekaii-Saab T
JAMA Oncol; 2022 May; 8(5):760-769. PubMed ID: 35238866
[TBL] [Abstract] [Full Text] [Related]
10. An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the breast.
Vranic S; Gatalica Z
Clin Breast Cancer; 2022 Jun; 22(4):e576-e585. PubMed ID: 35027319
[TBL] [Abstract] [Full Text] [Related]
11. CircRNA_0044556 diminishes the sensitivity of triple‑negative breast cancer cells to adriamycin by sponging miR‑145 and regulating nras.
Chen J; Shi P; Zhang J; Li Y; Ma J; Zhang Y; Liu H
Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913063
[TBL] [Abstract] [Full Text] [Related]
12. TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.
Grote I; Bartels S; Kandt L; Bollmann L; Christgen H; Gronewold M; Raap M; Lehmann U; Gluz O; Nitz U; Kuemmel S; Zu Eulenburg C; Braun M; Aktas B; Grischke EM; Schumacher C; Luedtke-Heckenkamp K; Kates R; Wuerstlein R; Graeser M; Harbeck N; Christgen M; Kreipe H
Cancer Med; 2021 Dec; 10(23):8581-8594. PubMed ID: 34779146
[TBL] [Abstract] [Full Text] [Related]
13. cancer Therapy Guided by Mutation Tests: Current Status and Perspectives.
Aleksakhina SN; Imyanitov EN
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681592
[TBL] [Abstract] [Full Text] [Related]
14. Bmi1 drives the formation and development of intrahepatic cholangiocarcinoma independent of Ink4A/Arf repression.
Guo J; Deng N; Xu Y; Li L; Kuang D; Li M; Li X; Xu Z; Xiang M; Xu C
Pharmacol Res; 2021 Feb; 164():105365. PubMed ID: 33307220
[TBL] [Abstract] [Full Text] [Related]
15. Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients.
Skriver SK; Jensen MB; Eriksen JO; Ahlborn LB; Knoop AS; Rossing M; Ejlertsen B; Laenkholm AV
Breast Cancer Res Treat; 2020 Nov; 184(1):123-133. PubMed ID: 32748297
[TBL] [Abstract] [Full Text] [Related]
16. MLL3 Induced by Luteolin Causes Apoptosis in Tamoxifen-Resistant breast cancer Cells through H3K4 Monomethylation and Suppression of the PI3K/AKT/mTOR Pathway.
Wu HT; Liu YE; Hsu KW; Wang YF; Chan YC; Chen Y; Chen DR
Am J Chin Med; 2020; 48(5):1221-1241. PubMed ID: 32668964
[TBL] [Abstract] [Full Text] [Related]
17. NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications.
Forschner A; Forchhammer S; Bonzheim I
J Dtsch Dermatol Ges; 2020 Dec; 18(12):1387-1392. PubMed ID: 32656925
[TBL] [Abstract] [Full Text] [Related]
18. Clinical relevance of H-RAS, K-RAS, and n-ras mRNA expression in primary breast cancer patients.
Banys-Paluchowski M; Milde-Langosch K; Fehm T; Witzel I; Oliveira-Ferrer L; Schmalfeldt B; Müller V
Breast Cancer Res Treat; 2020 Jan; 179(2):403-414. PubMed ID: 31646390
[TBL] [Abstract] [Full Text] [Related]
19. Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer.
Wang G; He Y; Sun Y; Wang W; Qian X; Yu X; Pan Y
Clin Transl Oncol; 2020 Jun; 22(6):813-822. PubMed ID: 31587152
[TBL] [Abstract] [Full Text] [Related]
20. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.
Ishihara S; Onoda N; Noda S; Asano Y; Tauchi Y; Morisaki T; Kashiwagi S; Takashima T; Ohira M
Int J Oncol; 2019 Nov; 55(5):1069-1076. PubMed ID: 31545405
[TBL] [Abstract] [Full Text] [Related]
[Next]
